News

PolyMedix, a biotechnology company, has successfully completed its first-in-man clinical study with the novel heparin antagonist drug PMX-60056. This ascending single-dose intravenous pharmacokinetic and safety study met the

Under the agreement, the three parties will jointly conduct a series of biomarker discovery studies for heart disease and early detection of metabolic syndrome – a combination of

It is reported that Technimed’s magnetic resonance imaging (MRI) technology and product Oxy-17 effectively renders an unaltered MRI scanner into a positron emission tomography (PET), PET/CT like metabolic

ImmunoCellular Therapeutics or IMUC, a biotechnology company, has signed an agreement with Formatech, a provider of product development and aseptic fill finish manufacturing services, for the development of

Vyteris, a biotechnology company, has initiated a Phase II clinical trial sponsored by its development partner, Ferring Pharmaceuticals. The trial evaluates Vyteris’s smart patch technology for the safety

US-based pharmaceutical company CEL-SCI has entered into an exclusive licensing agreement with Byron Biopharma under which CEL-SCI has granted Byron an exclusive license to market and distribute the

The company’s corporate controller, Len Ross, will become the principal financial and accounting officer. Paul Ashton, president and CEO of pSivida, said: “The company and the board of

Maureen Loftus, president of IBT, said: “IBT Laboratories was one of the first laboratories to develop a commercial pneumococcal assay to measure the concentration of antibodies produced in

Related to this, Biotie-Lundbeck licensing agreement terms have been amended. Under the terms of the amended agreement, Biotie is now eligible for up to E84 million in upfront